Stock 4530 HISAMITSU PHARMACEUTICAL CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hisamitsu Pharmaceutical Co., Inc.

Equities

4530

JP3784600003

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-04-25 am EDT 		5-day change 1st Jan Change
3,710 JPY -1.01% Intraday chart for Hisamitsu Pharmaceutical Co., Inc. -0.75% -13.94%
Apr. 11 Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024 MT
Jan. 12 Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HISAMITSU PHARMACEUTICAL CO., INC. Stock Hisamitsu Pharmaceutical Co., Inc.
-13.94% 1.83B
C
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 660B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.32% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.28% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.72% 219B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 196B
A+
NOVARTIS AG Stock Novartis AG
+6.83% 199B
B-
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4530 Stock
  4. Ratings Hisamitsu Pharmaceutical Co., Inc.